Cell transplantation for diabetes or possible June 22, 2017 Source: Health News Recently, Wang Weiqing and Wang Qidi, the endocrinologists of Shanghai Ruijin Hospital, published a research report in the journal Nature Communication, revealing a new mechanism of diabetes etiology and finding new targets for finding targeted drugs for diabetes. The key to the pathogenesis of diabetes is the down-regulation of functional islet β-cell capacity, which is regulated by the absolute number of beta cells and the functional maturation and differentiation of beta cells. The American Diabetes Association's 2017 National Diabetes Award winner Accili team first proposed a new mechanism of diabetes pathogenesis, in which beta cells differentiate into immature immature progenitor cells under metabolic stress and transdifferentiate to other types of cells. It can be seen that the loss of mature differentiation of β cells plays an important role in the pathogenesis of type 2 diabetes. But why is it different? Its molecular mechanism is not clear. The Endocrine Research Group of Shanghai Ruijin Hospital conducted an in-depth study on the pancreas histochemical staining at the critical time points of 4 β-cell maturation at 1 day, 4 days, 8 days, and 11 days after birth, and found the novel protein mTORC1. There has been a peak in expression. For the first time, the research team successfully constructed islet β-cells to selectively knock out mice with the key component of mTORC1, Raptor, and found that these mice developed dominant diabetes 4 weeks after birth and had serious insulin secretion defects. Studies have shown that Raptor can control the expansion of beta cell capacity after birth by regulating beta cell size and apoptosis. Since the loss of mature differentiation and differentiation of β cells is a disease pathological feature of some patients with type 2 diabetes, this type of patient is expected to restore the dedifferentiated naive β cells to mature β cells with normal glycogenotropic function by regulating mTORC1 activity. Effectively control diabetes. The original research results not only reveal the new pathogenesis of diabetes, but also find new targets for the treatment of diabetes. It is expected that by regulating the activity of mTORC1, maintaining the functional β-cell capacity and mature differentiation state of islets, and even inducing related cells to differentiate into mature β-cells with insulin secretion function in vitro, it provides a new possibility for clinical treatment of diabetes by cell transplantation. (Reporter Zhu Fan) We, Jiangsu YanFang Medical Technology Co., Ltd, commenced our medical gloves manufacturing in 2020. Currently, we possess a total of 12 high-capacity NBR Glove Dipping Production Lines. Industrial Nitrile Gloves,Nitrile Gloves Extra Large,Nitrile Powder Free Glove,Nitrile Powder Disposable Examination Gloves Jiangsu Yanfang Medical Technology Co.,Ltd. , https://www.yanfangchina.com
Likewise, we are not only certified with ISO9001, ISO13485 but also fully complied with the essential USFDA, CE Compliances, as well as obtaining relevant accreditation of FDA510K, EN455, and EN374.
Nonetheless, our NBR Examination, Chemotherapy, and Food Grade products are being well established in both US and Europe markets.
We look forward to cooperating and working closely with our valuable customers and stakeholders, who are seeking long-term business relationships in high-quality NBR glove supplies.